weight gain or hypoglycemia [1] . This article summarizes properties of short-and long-acting GLP-1 analogs, providing useful information for choosing the most appropriate compound for individual patients.
METHODS
The present paper is based on a review of recent publications on GLP-1 RA therapy and data This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
THE PHYSIOLOGICAL ROLE OF INCRETINS
The incretin notion is based on the observation that the insulin response from ingested glucose is larger and more sustained than that from intravenously administered glucose, suggesting that substances produced in the gastrointestinal tract in response to meals (''incretins'') stimulate insulin release [2, 3] . Two incretins have been (DPP-4). Long-term effects include stimulation of insulin synthesis [4] , an increase in b-cell proliferation and a reduction in apoptosis [5] . GLP-1 also improves the glycemic profile by inhibiting glucagon secretion, delaying gastric emptying, and reducing food intake. GLP-1 may also improve glucose disposal in peripheral tissues ( Fig. 1 ) [6] [7] [8] [9] . GLP-1 may have an affect on tissues that are not directly involved in glucose metabolism, including protection against myocardial ischemia or reperfusion injury [10, 11] . In blood vessels, it protects against endothelial dysfunction [12] , and promotes endothelium-independent artery relaxation [13] . It may have renal protective effects through increases in diuresis and natriuresis [14, 15] . These actions may lower blood pressure and have favorable effects on markers of cardiovascular risk, including brain natriuretic peptide and plasminogen activator inhibitor [16] .
PATHOPHYSIOLOGICAL MECHANISM
In subjects with normal glucose tolerance, the incretin effect accounts for about two-thirds of the insulin response to an oral load, whereas in patients with T2DM this value is less than 20% [3, 17] . Thus, the incretin response may be particularly important during the postprandial period and impaired response may lead to postprandial hyperglycemia.
The hypothesis that meal-induced GLP-1 secretion is impaired in patients with T2DM
versus control subjects is controversial. A large cross-sectional study by Toft-Nielsen et al. [18] showed that meal-induced GLP-1 responses were significantly reduced in patients with T2DM; however, in other studies they were similar to those in healthy participants (Fig. 2 ), and were not significantly different in a meta-analysis of 189 patients with T2DM and 217 healthy controls [19] .
A study performed under hyperinsulinemic-euglycemic clamp conditions, to maintain the same glucose and insulin levels in diabetic patients and matched control subjects, showed that GLP-1 response to oral glucose was reduced in patients with T2DM [20] . Because high glucose levels are known to induce DPP-4 expression [21], it has been hypothesized that chronic hyperglycemia may increase GLP-1 clearance, causing lower levels of circulating active GLP-1 [22] . However, no reduction in elimination rates of GLP-1 has been observed in patients with T2DM and mild-to-moderate hyperglycemia [23] . Thus, there appears to be some variation in GLP-1 secretion and/or inactivation, and in some cohorts the GLP-1 response was somewhat reduced, whereas in other studies such differences were not as apparent (Fig. 2) [19] . Impairment of the GLP-1 axis could be the consequence, rather than the cause, of hyperglycemia, establishing a vicious cycle that contributes to the maintenance of elevated glucose levels in T2DM, rather than to the pathogenesis of the disease. ) stimulates insulin biosynthesis and secretion and inhibits glucagon secretion in the pancreas, which in turn reduces hepatic gluconeogenesis. GLP-1 release also exerts protective effects on the heart and brain. Insulin sensitivity in the periphery is increased by improved insulin signaling and reduced gluconeogenesis. GI gastrointestinal, GIP gastric inhibitory polypeptide, GLP-1 glucagon-like peptide-1. Modified with permission from Pratley and Gilbert [106] 
INCRETIN-BASED THERAPIES
Twenty-seven years after the first publication by Nauck in Diabetologia [17] Integrated incremental GLP-1 (% of control) [66] , the daily dose was threefold higher (78.5 units) and this provided a 2.8% reduction in HbA 1c . The daily dose in the study comparing exenatide to insulin glargine [63] was 25 units compared to 47 units in the treat-to-target trial [67] . Thus, it remains to be determined how exenatide compares with optimal insulin dosing [68] . [88] , and insulin glargine [89] in patients treated with oral anti-hyperglycemic drugs. Exenatide once-weekly reduced HbA 1c to a greater extent than sitagliptin in drug-naive patients; it was not inferior to metformin, but did not achieve non-inferiority to pioglitazone [93] . The maximum-labeled dose of liraglutide (1.8 mg) provided better glycemic control than exenatide twice-daily [85] , sitagliptin [95] , insulin glargine [83] , and submaximal doses of glimepiride [80] and rosiglitazone [81] . The reductions in HbA1c noted for these long-acting GLP-1 receptor agonists in comparator-controlled trials were generally greater than those of oral anti-hyperglycemic drugs and basal insulin [81-83, 88-91, 93-95] .
It is important to note that, in the studies levels when compared with sitagliptin, glimepiride, pioglitazone and insulin lispro [98] .
Comparison data between albiglutide and lispro insulin in HARMONY-6 trial, in which it met non-inferiority criteria, suggest that this long-acting GLP-1 RA is a valid alternative to lispro insulin in add-on basal insulin. Another finding was the weight loss ability of albiglutide compared to weight gain in patients treated with lispro insulin [99] .
In the HARMONY-7 clinical trial, it was demonstrated that liraglutide at a dose of 0.6 mg titrated to 1.8 mg was more effective than albiglutide (at a dose of 30 mg titrated to 50 mg), but gastrointestinal adverse event was more frequent in liraglutide treatment [100] . Clearly, glycemic control is not the only goal of modern diabetes therapy. Insulin treatment often increases body weight, whereas incretin mimetics promote weight loss, which is recommended for most patients with this condition. Results from a pilot study [105] , suggest that the weight-lowering effect of exenatide may predominate over the insulin-induced weight gain. For this reason, adding a GLP-1 analog may help to increase quality of life during insulin therapy by compensating for its tendency to cause weight gain.
It should be emphasized that when added to either sulfonylureas or insulin, GLP-1 RAs are associated with increased risk of hypoglycemia. Therefore, accurate titration of insulin doses by glucose-self-monitoring is recommended when such combinations are prescribed.
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